Background: Cutaneous squamous cell carcinoma (cSCC) accounts for approximately 20% of non-melanoma skin cancers and predominantly affects older individuals due to cumulative ultraviolet (UV) exposure, with an incidence reported to be 5–10 times higher in patients aged >75 years. Anti–programmed cell death-1 (PD-1) monoclonal antibodies are now a standard systemic option for patients with unresectable or metastatic cSCC who are not candidates for curative surgery or radiotherapy. However, very old patients remain underrepresented in clinical trials, limiting the available evidence on efficacy and safety in this age group.
Bal et al. (Thu,) studied this question.